Is Harmony Biosciences Holdings (HRMY) overvalued? · P/E 14, rev $476.7M
Harmony Biosciences Holdings (HRMY) is a biotechnology company listed on NASDAQ.
This page asks whether Harmony Biosciences Holdings (HRMY) looks expensive on cached numbers — not a short thesis.
Latest reported HRMY revenue for 2026-06-30 was $476.7M. Net income was $107.9M. HRMY currently screens at market cap $1.96B and trailing P/E 13.6.
HRMY currently screens at market cap $1.96B and trailing P/E 13.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HRMY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HRMY stock page for the full model, not this heading.
Not investment advice.